Tourette
Syndrome Treatment Market, by Drug Class (Antiadrenergic Agents,
Antipsychotic Agents, Atypical Antipsychotics, Carbonic Anhydrase Inhibitor
Anticonvulsants, Others), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, and Online Pharmacies), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook,
and Opportunity Analysis, 2019 – 2026
Tourette syndrome is a rare and
severe neurological disorder which causes tics. Tic is a repetitive involuntary
movements, sudden, no rhythmic motor movements. It occurs due to the mutations of
the SLITRK1 gene, which plays an important role in development of nerve cells.
This syndrome usually occurs among the people of age between 2-15 years. There
are four types of tics: motor tics (uncontrolled body movements), vocal tics
(outburst of sound), simple tics (includes few parts of body) and complex tics
(contains several parts of body). Tourette’s syndrome is related to other
additional neurobehavioral problems like impulsivity, problems with reading and
writing, obsessive compulsive symptoms. It can be treated with neuroleptics;
haloperidol and pimozide are largely used medicines for Tourette syndrome.
Other medications such as guanfacine and clonidine are useful to treat the
severity of tics.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2642
Tourette Syndrome Treatment
Market Drivers
Drug approvals by regulatory
authorities is expected to boost the global tourette syndrome treatment market
growth. For instance, in October 23, 2017, Neurocrine Biosciences Inc.
announced that the Food Drug and Administration approved valbenazine orphan
drug designation to treat the pediatric patients with the Tourette syndrome.
Furthermore, in September 19, 2017, Teva Pharmaceutical Industries and
Nuvelution Pharma announced their partnership to develop AUSTEDO
(deutetrabenazine) tablets for the treatment of tics which is associated to
tourette syndrome in pediatric patients in the U.S. This partnership will drive
the development of Austedo (deutetrabenazine) in Tourette syndrome by bringing
new treatment options more quickly which are more necessary for the affected
young patients. These factors are expected to propel the global Tourette syndrome
treatment market growth.
Moreover, there are several
investigations made for the treatment of Tourette syndrome. For instance, in
March 2019, Wesley Medical Research was partnering with the University of
Sydney in Australia which carried the clinical trial to investigate whether the
medical cannabis could be used to treat the individuals with Tourette syndrome.
This trial will help examine efficacy and safety of cannabinoids on tic
frequency as well as the psychiatric symptoms associated with Tourette
syndrome.
Furthermore, the acquisitions of
companies drive the growth of the Tourette syndrome treatment market. For
instance, on August 14, 2018, Emalex Biosciences acquired the Psyadon
Pharmaceuticals and the rights to develop, register and market ecopipam, the
investigational drug of Psyadon Pharmaceuticals, which is used to treat the
Tourette syndrome in children less than 16 years of age.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/tourette-syndrome-treatment-market-2642
Tourette Syndrome Treatment Market
Regional Analysis
On the basis of region, the
Tourette syndrome market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa. North America is expected to
hold a dominant position in the Tourette syndrome treatment market due to
presence of large number of key players like Otsuka Holdings Co., Ltd,
AstraZeneca PLC, Catalyst Pharmaceutical Parteners, Inc. In terms of revenue,
U.S. contributes the major share of this syndrome treatment market. According
to the National Institute Of Neurological Disorders And Stroke(NIH), it is
estimated that around 2,00,000 Americans have the most severe form of Tourette
syndrome and as many as one in 100 shows milder or less complex symptoms such
as vocal tics.
Tourette Syndrome Treatment
Market Restraints
Withdrawal of the drugs in late
stages of clinical trials has hampered the global Tourette syndrome treatment
market growth. For instance, on December 12, 2018, Neurocrine Biosciences
revealed that the phase IIb study of valbenazine did not meet the primary
endpoint of reducing the tic severity in young people in moderate to severe
form of diseases.
Tourette Syndrome Treatment
Market Key Players
Some of the major players
operating in the global Tourette syndrome treatment market include Neurocrine
Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Apotex, Inc.,
Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals,
Torrent Pharmaceuticals Limited and Eli Lilly Pharmaceuticals.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2642
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment